MET activation (inclusive of amplification and METEx14 mutations) was observed in 6.9% of ERBB2amp NSCLC and showed comparable prevalence in GEC between ERBB2amp and ERBB2mut tumors (5.5% and 6.0%, respectively), being less common in other tumor types. This evidence concerns the gene MET and neoplasm.